Who's 'Afrezza' the FDA? Not MannKind, Still Plugging Away
By Randy Osborne
Staff Writer
Staff Writer
Thursday, January 10, 2013
As FDA-mandated Phase III trials near their finish with MannKind Corp.'s beleaguered inhaled insulin product Afrezza, Alfred Mann, CEO and major funder of the company, took to the lectern at the J.P. Morgan Healthcare Conference to deliver a familiar message: It works, the device is simple and patients will use it.
To continue reading subscribe now to Latest News
Learn More about Latest News
Already a subscriber? Sign In or Buy now to activate your subscription
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Reproduction, reposting content is strictly prohibited.